Preeclampsia Epidemiology Forecast 2025-2034

Preeclampsia epidemiology forecast indicates that preeclampsia is one of the leading causes of perinatal and maternal morbidity and morbidity, especially in middle- and low-income regions. The prevalence is estimated to be about 2% to 15% of all pregnancies, as per a study published in the International Journal of Environmental Research and Public Health (2023). Further, a 2021 review suggests that morbidity is more prevalent in developing countries, particularly in Africa and Latin America, whereas Asians appear to be at a lower risk for preeclampsia.

Preeclampsia Epidemiology Forecast Report Coverage

The “Preeclampsia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of preeclampsia. It projects the future incidence and prevalence rates of preeclampsia cases across various populations. The study covers age and type as major determinants of the preeclampsia population. The report highlights patterns in the prevalence of preeclampsia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on preeclampsia epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Preeclampsia Understanding: Disease Overview

Preeclampsia is a pregnancy complication that typically develops after the 20th week of pregnancy. It is characterized by high blood pressure and signs of damage to other organs. Preeclampsia is reported to lead to serious complications for both the mother and baby if left untreated. High blood pressure, protein in the urine, headaches, and swelling are common symptoms. Factors like poor blood flow to the placenta, immune system dysfunction, and genetic predisposition can increase the risk of preeclampsia.

In May 2023, Thermo Fisher Scientific announced that the United States Food and Drug Administration (FDA) approved two preeclampsia risk assessment assays. The Placental Growth Factor (PlGF) plus and soluble FMS-like tyrosine kinase-1 receptor (sFlt-1) tests, which take 30 minutes on the BRAHMS KRYPTOR analyzer, are the first to receive FDA clearance and breakthrough designation for helping manage preeclampsia risk.

Preeclampsia Epidemiology Perspective

The preeclampsia epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for the preeclampsia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for preeclampsia and their trends. The preeclampsia detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• The incidence of preeclampsia is reported to correlate with race and ethnicity. This pregnancy complication is the most prevalent among Hispanic and Black patients, accounting for roughly 26% of maternal deaths in this population segment in the United States.
• The preeclampsia prevalence is estimated to be about 2% to 15% of all pregnancies, according to a study published in the International Journal of Environmental Research and Public Health (2023).
• Preeclampsia is considered one of the leading causes of maternal morbidity, with over 500,000 fetal deaths and 70,000 maternal deaths attributed to the condition, as per the Centers for Disease Control and Prevention (CDC).
• Studies show that preeclampsia usually happens after the 20th week of pregnancy. However, some cases are also reported in the 6 weeks after giving birth.
• As per the Cleveland Clinic, preeclampsia accounts for approximately 15% of premature deliveries, which includes delivery before 37 weeks of pregnancy, in the United States.
• Maternal age is a major risk factor for preeclampsia, with studies indicating that women over 35 years old have a higher chance of developing preeclampsia than those aged 25-29 years.

Country-wise Preeclampsia Epidemiology Segment

The preeclampsia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of preeclampsia varies significantly between countries due to differences in the prevalence of hypertension and diabetes, healthcare infrastructure, maternal age, nutritional status, genetics, access to prenatal care, and socio-economic factors. In the United States, preeclampsia occurs in around 1 out of 25 pregnancies, as per the March of Dimes, a United States nonprofit organization.

Preeclampsia Epidemiology: Treatment Overview

Preeclampsia therapeutics to control blood pressure, such as methyldopa or labetalol, are given in mild preeclampsia cases. Regular urine tests are advised to check for protein levels. Alpha-2 agonists (clonidine) and vasodilators (hydralazine) are widely used antihypertensive drugs that have shown efficacy without adverse effects on the fetus. Nifedipine and clonidine are medications prescribed for non-compliant patients as they offer less frequent dosing options.

Key Questions Answered

• What are the key findings of preeclampsia epidemiology in the 8 major markets?
• What will be the total number of patients with preeclampsia across the 8 major markets during the forecast period?
• What was the country-wise preeclampsia epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of preeclampsia cases during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of preeclampsia during the forecast period of 2025-2034?
• What are the currently available treatments in the global preeclampsia market?
• What are the disease risks, signs, symptoms, and unmet needs of preeclampsia?

Scope of the Preeclampsia Epidemiology Report

• The preeclampsia epidemiology forecast covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of preeclampsia based on several factors.
• The Preeclampsia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The preeclampsia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.